Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 2012, 08:04 AM   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this
Labels: AEZS, Analysts New Coverage, Market News

Related Stocks

Chart Stock Name Last Change Volume 
  AEZS 2.11 -0.02 (0.94%) 103,500 

  Be the first to like this.
 


 

3407  4155  809  190 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 CMCSA 33.81+1.02 
 RAD 2.02+0.05 
 SWN 5.47+0.20 
 NVCN 0.043+0.005 
 BAC 28.99-0.30 
 GE 13.05+0.29 
 ESV 6.35+0.37 
 T 31.69+0.09 
 MU 57.10-2.34 
 RENN 2.36+1.438 
Partners & Brokers